JP2013527844A5 - - Google Patents

Download PDF

Info

Publication number
JP2013527844A5
JP2013527844A5 JP2013505568A JP2013505568A JP2013527844A5 JP 2013527844 A5 JP2013527844 A5 JP 2013527844A5 JP 2013505568 A JP2013505568 A JP 2013505568A JP 2013505568 A JP2013505568 A JP 2013505568A JP 2013527844 A5 JP2013527844 A5 JP 2013527844A5
Authority
JP
Japan
Prior art keywords
acid
formula
cis
composition
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013505568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013527844A (ja
JP6250389B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2011/001294 external-priority patent/WO2011132084A2/en
Publication of JP2013527844A publication Critical patent/JP2013527844A/ja
Publication of JP2013527844A5 publication Critical patent/JP2013527844A5/ja
Application granted granted Critical
Publication of JP6250389B2 publication Critical patent/JP6250389B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013505568A 2010-04-19 2011-04-19 内因性レチノイド欠損に関連する視覚障害を治療する又は改善する治療計画及び治療方法 Expired - Fee Related JP6250389B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US32576310P 2010-04-19 2010-04-19
US61/325,763 2010-04-19
US40743610P 2010-10-27 2010-10-27
US61/407,436 2010-10-27
US201161447611P 2011-02-28 2011-02-28
US61/447,611 2011-02-28
PCT/IB2011/001294 WO2011132084A2 (en) 2010-04-19 2011-04-19 Therapeutic regimen and method for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2015187459A Division JP2016014047A (ja) 2010-04-19 2015-09-24 内因性レチノイド欠損に関連する視覚障害を治療する又は改善する治療計画及び治療方法
JP2017189573A Division JP2017222721A (ja) 2010-04-19 2017-09-29 内因性レチノイド欠損に関連する視覚障害を治療する又は改善する治療計画及び治療方法

Publications (3)

Publication Number Publication Date
JP2013527844A JP2013527844A (ja) 2013-07-04
JP2013527844A5 true JP2013527844A5 (cg-RX-API-DMAC7.html) 2014-07-24
JP6250389B2 JP6250389B2 (ja) 2017-12-20

Family

ID=44788663

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013505568A Expired - Fee Related JP6250389B2 (ja) 2010-04-19 2011-04-19 内因性レチノイド欠損に関連する視覚障害を治療する又は改善する治療計画及び治療方法
JP2015187459A Pending JP2016014047A (ja) 2010-04-19 2015-09-24 内因性レチノイド欠損に関連する視覚障害を治療する又は改善する治療計画及び治療方法
JP2017189573A Pending JP2017222721A (ja) 2010-04-19 2017-09-29 内因性レチノイド欠損に関連する視覚障害を治療する又は改善する治療計画及び治療方法
JP2019120244A Pending JP2019178162A (ja) 2010-04-19 2019-06-27 内因性レチノイド欠損に関連する視覚障害を治療する又は改善する治療計画及び治療方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2015187459A Pending JP2016014047A (ja) 2010-04-19 2015-09-24 内因性レチノイド欠損に関連する視覚障害を治療する又は改善する治療計画及び治療方法
JP2017189573A Pending JP2017222721A (ja) 2010-04-19 2017-09-29 内因性レチノイド欠損に関連する視覚障害を治療する又は改善する治療計画及び治療方法
JP2019120244A Pending JP2019178162A (ja) 2010-04-19 2019-06-27 内因性レチノイド欠損に関連する視覚障害を治療する又は改善する治療計画及び治療方法

Country Status (18)

Country Link
US (3) US9173856B2 (cg-RX-API-DMAC7.html)
EP (1) EP2563350B1 (cg-RX-API-DMAC7.html)
JP (4) JP6250389B2 (cg-RX-API-DMAC7.html)
KR (2) KR101851249B1 (cg-RX-API-DMAC7.html)
CN (2) CN107308143A (cg-RX-API-DMAC7.html)
AU (3) AU2011244024B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012026939A2 (cg-RX-API-DMAC7.html)
CA (1) CA2796991A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012002942A1 (cg-RX-API-DMAC7.html)
CO (1) CO6640227A2 (cg-RX-API-DMAC7.html)
HK (1) HK1246171A1 (cg-RX-API-DMAC7.html)
IL (1) IL222567A (cg-RX-API-DMAC7.html)
MX (1) MX339834B (cg-RX-API-DMAC7.html)
NO (1) NO20121362A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ603331A (cg-RX-API-DMAC7.html)
RU (1) RU2622763C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201507819VA (cg-RX-API-DMAC7.html)
WO (1) WO2011132084A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2546005C2 (ru) 2009-09-15 2015-04-10 Кью Эл Ти ИНК. Фармацевтические составы, содержащие 9-цис-ретиниловые сложные эфиры в липидном наполнителе
SG10201507819VA (en) 2010-04-19 2015-10-29 Quadra Logic Tech Inc Therapeutic Regimen And Methods For Treating Or Ameliorating Visual Disorders Associated With An Endogenous Retinoid Deficiency
AU2013232697B2 (en) * 2012-03-01 2017-10-19 Eluminex Biosciences (Suzhou) Limited Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
WO2015023902A2 (en) * 2013-08-14 2015-02-19 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with impaired dark adaptation and/or impaired low luminance vision
EP3690045A2 (en) 2017-09-29 2020-08-05 Toolgen Incorporated Gene manipulation for treatment of retinal dysfunction disorder
EP4161502A4 (en) * 2020-06-09 2024-07-10 Eluminex Biosciences (Suzhou) Limited Methods of treating visual disorders using daily low dosing of a retinoid compound

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196078A (en) 1962-01-30 1965-07-20 Ortho Pharma Corp Process for combating retinits pigmentosa
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
DE2300107C2 (de) 1973-01-03 1982-03-11 Basf Ag, 6700 Ludwigshafen Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen
CH590222A5 (cg-RX-API-DMAC7.html) 1973-08-21 1977-07-29 Hoffmann La Roche
US4022913A (en) 1973-09-13 1977-05-10 Hoffmann-La Roche Inc. High potency vitamin A compositions
DE2456959A1 (de) 1974-12-03 1976-06-16 Basf Ag 4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen
US4532133A (en) 1983-05-24 1985-07-30 Basf Wyandotte Corporation Low temperature stable, emulsifiable vitamin A concentrates
CA1282326C (en) 1984-12-14 1991-04-02 Paul J. Jarosz Pharmaceutical composition containing 13-cis vitamin a acid as the active ingredient
JPS61275266A (ja) 1985-05-28 1986-12-05 Taisho Pharmaceut Co Ltd レチノイド誘導体
CZ282548B6 (cs) 1992-01-22 1997-08-13 F. Hoffmann-La Roche Ag Farmaceutický přípravek
US5310764A (en) 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
JPH06340525A (ja) 1993-06-02 1994-12-13 Lion Corp 安定な低眼刺激性ビタミンa類可溶化点眼剤
EP0754046A1 (en) 1994-04-04 1997-01-22 FREEMAN, William R. Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
US5425560A (en) 1994-04-21 1995-06-20 Strattec Security Corporation Squeeze latch
RU2106843C1 (ru) 1994-06-29 1998-03-20 Красноярская государственная медицинская академия Способ лечения близорукости
JPH08198746A (ja) 1995-01-18 1996-08-06 Lion Corp 可溶化点眼剤
US5837728A (en) 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US5489611A (en) 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
US5620970A (en) 1995-06-05 1997-04-15 Alcon Laboratories, Inc. Topical ophthalmic carbonic anhydrase inhibitor formulations
AU6390096A (en) 1995-07-20 1997-02-18 Pharmacia & Upjohn Company Stable clear solutions of non-steroidal anti-inflammatory drugs for incorporation into gelatin capsules
US5716627A (en) 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
EP0908179A1 (en) 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
ZA989513B (en) 1997-10-21 1999-04-21 Alcon Lab Inc Compositions containing histamine H2 agonists and methods of use in treating dry eye
US6391924B1 (en) 1997-12-10 2002-05-21 Hampar Karageozian Taurine derivatives useable in the treatment of ophthalmic disorders
US6552009B2 (en) 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6372463B1 (en) 1999-05-06 2002-04-16 The President & Fellows Of Harvard College Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof
US6300328B1 (en) 1999-08-06 2001-10-09 Alcon Universal Ltd. Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
US20020028849A1 (en) 2000-04-18 2002-03-07 Godkin James D. Use of retinol in assisted-reproduction protocols
US6696069B2 (en) 2000-06-30 2004-02-24 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof
US20040077604A1 (en) 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
EP1261623B1 (en) 2001-01-11 2009-11-04 Chebigen Inc. New retinol derivatives, the method of preparations and the uses thereof
CA2442670A1 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
ITMI20012366A1 (it) 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
JP2005519878A (ja) 2001-11-30 2005-07-07 キネテク ファーマシューティカルズ,インコーポレーテッド ヒドラゾノピラゾール誘導体および治療剤としてのその使用
CA2474154A1 (en) 2002-01-18 2003-07-24 Tatton Technologies, Llc. Methods for treating eye disorders
US20030215413A1 (en) 2002-03-22 2003-11-20 L'oreal Compositions containing stabilized retinoid
US20040097587A1 (en) 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
CN1741811A (zh) 2002-03-29 2006-03-01 马克西姆医药公司 Rom产生与释放抑制剂治疗和预防眼内损伤的用途
JP3854524B2 (ja) * 2002-04-01 2006-12-06 ピアス株式会社 油溶性成分安定化組成物及びその組成物を配合した化粧料、並びに油溶性成分の安定化方法
EP1527774A1 (en) 2003-11-03 2005-05-04 Basilea Pharmaceutica AG New formulation for retinoid-containing soft gelatin capsules
US20060281821A1 (en) 2003-03-14 2006-12-14 Krzysztof Palczewski Retinoid replacements and opsin agonists and methods for the use thereof
EP1510133A1 (en) 2003-09-01 2005-03-02 Belovo S.A., Egg Science & Technology Balanced oil composition
ES2563733T3 (es) 2003-09-04 2016-03-16 The Uab Research Foundation Procedimiento y aparato para la detección del deterioro en la adaptación a la oscuridad
US7706863B2 (en) 2004-01-21 2010-04-27 University Of Washington Methods for assessing a physiological state of a mammalian retina
WO2005079774A2 (en) 2004-02-17 2005-09-01 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
CN1964706A (zh) 2004-03-17 2007-05-16 拉斯·M·拉森 通过抑制视觉周期预防视网膜病
AU2005257997B2 (en) * 2004-06-18 2012-04-05 University Of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
KR100862930B1 (ko) * 2004-06-23 2008-10-13 시리온 테라퓨틱스, 인크. 레티닐 유도체를 사용하여 안 증상을 치료하기 위한 방법및 조성물
US20060240098A1 (en) 2004-07-14 2006-10-26 Aphios Corporation Formulations for hyperforin-enriched hypericum fractions
AU2005287343A1 (en) 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
WO2006039551A2 (en) 2004-09-30 2006-04-13 The Regents Of The University Of California Local administration of retinoids to treat deficiencies in dark adaptation
US20060177392A1 (en) 2005-02-10 2006-08-10 William Walden Oil-based composition for acne
PT1903866E (pt) 2005-11-07 2016-06-09 Murty Pharmaceuticals Inc Distribuição melhorada de tetra-hidrocanabinol
US8202541B2 (en) 2006-02-07 2012-06-19 U.S. Nutraceuticals, LLC Dietary supplement composition for blood lipid health
AU2007277032A1 (en) 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Opsin stabilizing compounds and methods of use
CN107652212B (zh) 2007-01-15 2019-11-15 于崇曦 维生素a酸类和类维生素a酸化合物的前药
JP5149388B2 (ja) 2007-09-12 2013-02-20 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 黄斑変性症を処置するための組成物及び方法
US8324270B2 (en) * 2008-02-11 2012-12-04 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
RU2546005C2 (ru) 2009-09-15 2015-04-10 Кью Эл Ти ИНК. Фармацевтические составы, содержащие 9-цис-ретиниловые сложные эфиры в липидном наполнителе
SG10201507819VA (en) 2010-04-19 2015-10-29 Quadra Logic Tech Inc Therapeutic Regimen And Methods For Treating Or Ameliorating Visual Disorders Associated With An Endogenous Retinoid Deficiency
AU2013232697B2 (en) 2012-03-01 2017-10-19 Eluminex Biosciences (Suzhou) Limited Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency

Similar Documents

Publication Publication Date Title
US20240024265A1 (en) Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
JP6941109B2 (ja) Fxrアゴニストを使用するための方法
RU2014139666A (ru) Схемы лечения и способы улучшения зрительной функции при расстройствах зрения, связанных с дефицитом эндогенного ретиноида
US10905671B2 (en) Method of using omega 3 fatty acids to treat diseases which involve damage to the nervous system
AU2012307524B2 (en) Use of omega fatty acids for treating disease
CN105848652A (zh) 用于治疗肠渗透性过高的酪氨酸羟化酶抑制剂
US10363235B2 (en) Compositions comprising 15-HEPE and methods of treating or preventing fibrosis using same
US20200093775A1 (en) Compositions And Methods For Treating Intestinal Hyperpermeability
JP2013544275A (ja) 葉酸−ラミプリルの組合せ:細胞保護性、神経保護性、および網膜保護性の眼科用組成物
KR101851249B1 (ko) 내인성 레티노이드 결핍과 연관된 시각 장애의 치료 또는 완화를 위한 치료용 조성물, 제형 및 키트
US12364676B2 (en) Compositions and methods for treating retinopathy
JP2014510156A5 (cg-RX-API-DMAC7.html)
US9505709B2 (en) Compositions and methods relating to ionic salts of peptides
US11622954B2 (en) Estrogen receptor ligands, compositions and methods related thereto
US20170128462A1 (en) Methods for treating female sexual dysfunction while decreasing cardiovascular risk
JP6296795B2 (ja) 改善されたワクチン組成物
KR20230158076A (ko) 눈 질환을 치료하기 위한 방법 및 조성물
JP2016513125A (ja) 眼の疾患および障害を治療するための方法
JP2024526939A5 (cg-RX-API-DMAC7.html)
WO2022173043A1 (ja) ウルソデオキシコール酸またはその塩を含有する水性医薬組成物
KR20210107168A (ko) 지질 이상증 치료제
WO2015023902A2 (en) Therapeutic regimens and methods for improving visual function in visual disorders associated with impaired dark adaptation and/or impaired low luminance vision
EP4731247A1 (en) Compositions and methods for treating acromegaly
TWI788582B (zh) ω3脂肪酸之自體乳化製劑及自體乳化組成物
JP2023554524A5 (cg-RX-API-DMAC7.html)